DNMT1 and cancer: The Food and Drug Administration (FDA) has approved two DNMT inhibitors, Azacitidine (Vidaza) and Decitabine (Dacogen) [18], for the treatment of certain types of cancer, particularly myelodysplastic syndromes and acute myeloid leukemia.